Becton's simplified MSRA (methicillin-resistant Staphylococcus aureus) test:
This article was originally published in Clinica
Executive Summary
Becton Dickinson (BD) has received US FDA 510(k) clearance for a simplified test for detecting methicillin-resistant Staphylococcus aureus (MRSA). The BBL CHROMagar MRSA product consists of a prepared plated medium that allows patients colonised with the bacteria to be identified more quickly and easily than with the time-consuming and labour-intensive processes currently available, claimed the Baltimore, Maryland firm. It enables the direct detection and identification of most MRSA within 24 hours. The cost benefits associated with reducing nosocomial infections can be significant, the company added.